Incivek on formulary

Quote

Anonymous

Guest
Since noone is reallly disputing that Insivek is so much better than Victrelis, why aren't we able to get preferential tier placement on any formularies? I know we have close to 80% market share, but we should have higher. We shouldn't be parity on 99%
 






Why would you give a plan a discount to get a preferred tier and lose revenue when you can be at parity and continue to build higher share at the maximum revenue? Do the math not worth it.
 






Also, what does "preferred" get you. Less copay for patient? Copay programs take the advantage away.

Very few really NDC block. Let the MDs have the choice at parity and fight it out in the offices.
 






Anonymous said:
Since noone is reallly disputing that Insivek is so much better than Victrelis, why aren't we able to get preferential tier placement on any formularies? I know we have close to 80% market share, but we should have higher. We shouldn't be parity on 99%
Click to expand...

I would actually believe your a VRTX rep if you spelled your product right....total Merck crap. Enjoy getting your ass kicked.
 






























it happens because your VA people are inept. and your drug is over priced. you can treat 2 victrelis patients for one of yours. actually, you can probably treat 4 vic pats for every one inc patients because you have to manage all the side effects. more people get to eot with vic, not having to stop therapy b/c of AEs. its the logical choice if you think about it, really. is there a plan that has inc exclusive? vic does. run a cost to benefit anal and you will see. in the end vic will win.
 












Bottomline: Vertex is in trouble. SE's are killing you. Docs are waking up and realizing that all the downplaying of side effects the reps have been doing has cost them alot of time, and there patients alot of misery.

Watch the MS disappear in the next few months. Badmouth me if you choose, but time will tell. Way too many patients discontinuing and/or being hospitalized. Let alone, your PI will not be used with any other drugs because of the profile.

Better hope that CF drug pans out! Otherwise, start looking.
 






Anonymous said:
Bottomline: Vertex is in trouble. SE's are killing you. Docs are waking up and realizing that all the downplaying of side effects the reps have been doing has cost them alot of time, and there patients alot of misery.

Watch the MS disappear in the next few months. Badmouth me if you choose, but time will tell. Way too many patients discontinuing and/or being hospitalized. Let alone, your PI will not be used with any other drugs because of the profile.

Better hope that CF drug pans out! Otherwise, start looking.
Click to expand...

Market share says otherwise. Nice try
 












Anonymous said:
LOL.... Ummm... CHECK AGAIN!!! When you guys were comparing yourselves to lead in, you looked GREAT!!! (Cause the patient was on Victrelis yet)... CHECK AGAIN!!!! Hahahahahaha....
Click to expand...


Huh? You have a 20% market share, we have 80%, what are you chirping about? Please come back when you have at least 35% of the market.
 






Anonymous said:
Huh? You have a 20% market share, we have 80%, what are you chirping about? Please come back when you have at least 35% of the market.
Click to expand...

LMAO!!! NO YOU DON'T!! And you KNOW IT... You guys didn't do yourselves any favors running around yelling 80% share, cause all your competitor has to do now is say to the doc "What is their share NOW???"... LOL... The answer??? "Around 69% and DROPPING!!!".... Your shares have dropped an average of 9% MONTHLY since launch!! And you're getting it HANDED to you in So Cal!! It's SINKING SHIP!!!!! And I don't even work for either company! HA!
 












Top Bottom
Back
Quote